Nantahala Capital Management’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.28M | Hold |
2,000,000
| – | – | 0.08% | 133 |
|
|
2026
Q1 | $2.78M | Hold |
2,000,000
| – | – | 0.1% | 124 |
|
|
2025
Q4 | $3.22M | Hold |
2,000,000
| – | – | 0.11% | 118 |
|
|
2025
Q3 | $5.46M | Hold |
2,000,000
| – | – | 0.19% | 101 |
|
|
2025
Q2 | $7.28M | Hold |
2,000,000
| – | – | 0.29% | 69 |
|
|
2025
Q1 | $3.84M | Buy |
+2,000,000
| New | +$4.08M | 0.15% | 84 |
|
|
2022
Q1 | – | Sell |
-4,918,565
| Closed | -$10.5M | – | 124 |
|
|
2021
Q4 | $11.1M | Sell |
4,918,565
-59,630
| -1% | -$163K | 0.39% | 52 |
|
|
2021
Q3 | $14.3M | Sell |
4,978,195
-191,868
| -4% | -$548K | 0.45% | 53 |
|
|
2021
Q2 | $19.6M | Buy |
5,170,063
+19,244
| +0.4% | +$64.8K | 0.56% | 42 |
|
|
2021
Q1 | $17.4M | Sell |
5,150,819
-1,889,668
| -27% | -$6.81M | 0.51% | 45 |
|
|
2020
Q4 | $19.7M | Buy |
7,040,487
+1,293,864
| +23% | +$3.78M | 0.61% | 43 |
|
|
2020
Q3 | $14.4M | Sell |
5,746,623
-354,488
| -6% | -$3.11M | 0.44% | 52 |
|
|
2020
Q2 | $82.9M | Sell |
6,101,111
-458,367
| -7% | -$4.74M | 2.5% | 7 |
|
|
2020
Q1 | $49.7M | Sell |
6,559,478
-177,642
| -3% | -$1.38M | 1.86% | 10 |
|
|
2019
Q4 | $42.6M | Buy |
6,737,120
+947,559
| +16% | +$4.5M | 1.31% | 21 |
|
|
2019
Q3 | $22.7M | Hold |
5,789,561
| – | – | 0.84% | 31 |
|
|
2019
Q2 | $28M | Buy |
5,789,561
+848,500
| +17% | +$4.83M | 0.86% | 31 |
|
|
2019
Q1 | $40.5M | Sell |
4,941,061
-123,028
| -2% | -$844K | 1.26% | 20 |
|
|
2018
Q4 | $28M | Buy |
5,064,089
+339,878
| +7% | +$2.66M | 0.86% | 30 |
|
|
2018
Q3 | $41.7M | Buy |
4,724,211
+201,100
| +4% | +$1.8M | 1.12% | 26 |
|
|
2018
Q2 | $45.1M | Buy |
4,523,111
+1,136,968
| +34% | +$11.4M | 1.83% | 18 |
|
|
2018
Q1 | $32.3M | Buy |
3,386,143
+1,452,276
| +75% | +$20.3M | 1.45% | 20 |
|
|
2017
Q4 | $28.8M | Buy |
1,933,867
+565,920
| +41% | +$9.39M | 1.28% | 19 |
|
|
2017
Q3 | $26.9M | Sell |
1,367,947
-780,676
| -36% | -$12M | 1.32% | 17 |
|
|
2017
Q2 | $30.9M | Sell |
2,148,623
-131,908
| -6% | -$1.67M | 2.45% | 14 |
|
|
2017
Q1 | $21M | Buy |
2,280,531
+48,123
| +2% | +$470K | 2.34% | 12 |
|
|
2016
Q4 | $23.2M | Buy |
2,232,408
+317,400
| +17% | +$2.73M | 2.41% | 12 |
|
|
2016
Q3 | $17.3M | Buy |
1,915,008
+234,618
| +14% | +$1.99M | 2.09% | 14 |
|
|
2016
Q2 | $12.6M | Buy |
1,680,390
+333,064
| +25% | +$2.91M | 1.36% | 21 |
|
|
2016
Q1 | $12.1M | Buy |
1,347,326
+1,125,652
| +508% | +$9.13M | 1.25% | 22 |
|
|
2015
Q4 | $2.86M | Buy |
+221,674
| New | +$2.26M | 0.37% | 51 |
|
Other funds holding AKBA
Nantahala Capital Management's AKBA Position: Q2 2026 in Review
Nantahala Capital Management held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 2,000,000 shares worth $2.28M. The position accounts for 0.08% of the portfolio, ranked #133.
Nantahala Capital Management first reported a position in AKBA in Q4 2015 and has held it in 31 quarters since. The position peaked at $82.9M in Q2 2020. 170 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.
- Nantahala Capital Management held 2,000,000 shares of Akebia Therapeutics worth $2.28M as of Q2 2026.
- Nantahala Capital Management left its Akebia Therapeutics share count unchanged in Q2 2026.
- Akebia Therapeutics made up 0.08% of Nantahala Capital Management's portfolio in Q2 2026, its #133 holding.
- Nantahala Capital Management first reported a position in Akebia Therapeutics in Q4 2015 and has held it in 31 quarters since.
- Nantahala Capital Management's Akebia Therapeutics position peaked at $82.9M in Q2 2020.
- 170 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.
Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.